2019 Industry Insights on Immunohematology Market| Key Players: Bio-Rad Laboratories , Thermo Fisher Scientific, Beckman Coulter, Hologic, Inc., Siemens , Grifols, Ortho Clinical Diagnostics

The Immunohematology Market set is expected to witness 5.8% CAGR from 2018 to 2024 new research report by Global Market Insights.

U.S. immunohematology market will experience 5.6% CAGR and is expected to grow substantially during the forecast timeframe. High market growth can be attributed to the increasing prevalence of leukemia. According to Leukemia Lymphoma Society, in 2018 around 174,250 people in the U.S. are expected to be diagnosed with myeloma, leukemia and lymphoma. Moreover, rising awareness regarding genetic testing for blood disorders amongst the American people substantially will increase demand for immunohematology analyzers escalating the industry growth during the forecast timeframe
Technological advancements in immunohematology devices will augment the industry growth over forthcoming years.

Currently developed immunohematology analyzers are integrated with advanced technology that enables them to perform accurate and efficient analysis. For instance, immunohematology analyzers developed by BioRad Laboratories provides accurate results and the innovative instrument design enables improved productivity helping to generate quick analysis of the sample being processed. Moreover, key industry players also focus their R&D efforts in introducing semi-automated and fully automated immunohematology systems that further facilitates the sample analyzing process. Reduction in analysis time and minimization of errors due to automation will trigger the adoption of immunohematology analyzers stimulating the industry growth over upcoming years.


Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/1652

Increasing prevalence of hematological disorders globally will positively impact the industry growth during forecast timeframe. Most common types of blood conditions include thrombocytopenia, blood cancers, blood clots and anemia. High prevalence of blood cancer will ensure high industry growth over foreseeable future. For instance, according to Janssen, 900,000 people globally are diagnosed with blood cancer every year. There are over 140 different types of blood cancer with varying complexity requiring critical monitoring and availability of technologically advanced immunohematology analyzers will prove beneficial for industry growth as it ensures accurate diagnosis leading to quicker patient recovery. However, stringent regulatory policies may hamper the immunohematology industry growth.

Analyzers segment was valued at USD 632 million in 2017 and considerable revenue size can be associated with the increasing demand for technologically advanced analyzers used in diagnosing the blood disorders. Hematology systems integrated with reticulocyte count analysis technique will ensure accurate diagnosis impacting the segmental growth positively in forthcoming years. Also, industry players such as Siemens focus efforts on introducing automation in analyzers that helps in reducing errors ultimately increasing the demand for analyzers.

Reagents segment will experience 5.9% CAGR during the forecast timeframe. Superior quality reagents manufactured by companies such as Abbott Laboratories and Beckman Coulter have resulted in high demand. Moreover, high growth will be due to continuous consumption of reagents in detection of blood disorders. Furthermore, increasing prevalence of leukemia in emerging economies will increase demand for immunohematology reagents thereby, escalating the segmental growth in upcoming years.

Browse Full Report Details @ https://www.gminsights.com/industry-analysis/immunohematology-market

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
 Bio-Rad Laboratories
 Thermo Fisher Scientific
 Beckman Coulter
 Hologic, Inc.
 Siemens
 Grifols
 Ortho Clinical Diagnostics
 Immucor, Inc.
 BD
 Abbott
 ANTISEL SA Roche Diagnostics
PCR segment accounted for 35.9% in 2017 and is expected to show similar growth trends over the upcoming years. Considerable segmental revenue share can be accounted to the growing applications of PCR in diagnosis of hereditary blood disorders. For instance, according to virtual medical center, currently around 15 million patients have been diagnosed with thalassemia genetic blood disorder that should increase the demand for PCR technique thereby, augmenting segment growth.

Biochips segment will experience 5.8% CAGR during the forecast timeframe. Extensive use of biochips in identifying blood group genotyping will boost business growth over the upcoming years. For instance, according to International Society of Blood Transfusion, currently there are around 33 blood groups representing more than 300 antigens and biochips enabling analysis of many tests simultaneously are utilized in determining the complex blood groups. Aforementioned factors coupled with increasing number of blood banks will boost the demand for biochips elevating segmental growth.
Hospitals segment was valued at USD 1.0 billion in 2017 and is expected to have substantial revenue size during the forecast timeframe. Significant revenue size can be attributed to the increasing use of immunohematology analyzers in detecting patients suffering from leukemia and other chronic blood disorders. Moreover, automation introduced in the immunohematology devices reduces the chances of errors increasing its adoption among hospitals. Furthermore, development in public healthcare sectors in advanced countries such as U.S. will ensure availability of technologically advanced immunohematology analyzers stimulating the segmental growth.

Blood banks segment accounted for 18.2% revenue share in 2017. High preference for technologically advanced immunohematology devices for determining the blood groups while performing transfusion procedures in blood banks will positively influence the segmental growth. According to American Red Cross, in the U.S., around 36,000 units of red blood cells are needed every day and nearly 21 million blood components are transfused every year that should drive the segment growth during forecast timeframe.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1652

India immunohematology market was valued at USD 68.2 million in 2017. High number of blood transfusions will favor the India immunohematology market growth. According to Red Cross Society, annually 12 million units of blood are required in India that ensures high demand for immunohematology devices that facilitates the process of blood group determination. Furthermore, rising number of blood banks along with growing advances in transfusion medicines will boost the demand for immunohematology devices propelling the industry growth in near future.

About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog: http://solutionrocket.com

This release was published on openPR.